from PubMed database for published articles dated from January 2007 to September 2013. The search strategy involved the use of the following search string: "warfarin" AND "atrial fibrillation" AND "dabigatran" AND "stroke prevention." Moreover, we manually screened through the reference lists of the available full-text articles and performed forward-tracking of the relevant articles in search of additional studies that fit our review objectives.
Inclusion and exclusion criteria
First, the type of population, choice of intervention and comparison, and primary outcome of the literature were determined. [6] The population to be investigated was patients with AF. Trials comparing head-to-head warfarin and dabigatran were included in the study. Finally, outcomes of interest were stroke and major bleeding which were explained in detail in the endpoint definition.
Only randomized controlled trials in the form of full-text articles or summary abstracts were selected. [6] However, cohort studies with large sample size (n = 50,000) were also considered. Furthermore, human studies presented in English language and population with additional high-risk factors of stroke such as previous stroke or transient ischemic attack (TIA) were also criteria of study inclusion for the review.
Apart from that, studies were excluded if they were (1) observational studies or case reports; (2) trials with no comparator (i.e., warfarin alone); and (3) patients with other coexisting condition such as chronic kidney disease, abnormal liver function, and pregnancy.
The assessment of the literature was done based on the primary and secondary outcomes defined during the literature search.
Endpoint definition
Primary endpoints • Stroke, defined as a neurological deficiency, is characterized by an acute focal injury of the central nervous system (CNS) of a vascular origin which lasts for more than 24 h. It includes CNS infarction, ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. [7] Likewise, TE is the umbrella term covering stroke, TIA, systemic or pulmonary embolism, and embolic complications to viscera and extremities [6] • Major bleeding which involves fatal or life-threatening retroperitoneal, intracranial, intraocular, or intraspinal bleeding; subdural hematomas, or bleeding requiring surgery or transfusion of 2 U or associated with a decrease in hemoglobin of 2.0 g/L.
[8]
Secondary endpoints
• Fatal or nonfatal adverse effects during treatment, excluding hemorrhage [6] • All-cause death during treatment or follow-up.
[6]
Data interpretation
Due to the complexity associated with the traditional analysis of RR and 95% confidence interval, mean event rate was calculated for the effects of warfarin and dabigatran (110 mg and 150 mg) in terms of TE (i.e., stroke), major bleeding, and net clinical benefit [ Table 1 ]. In this review, event rate was the major determinant of outcome measure. Based on the Connolly et al. [9] 1.7 [16] 0.6 0.8 0.3 0.6 1.7 0.6 NA NA NA Hart et al. [17] 0. [19] 1.8
1.7 1.1 3.9 2.9 3.1 NA NA NA Gagne et al. [20] 2.7 2.1 1.9 4.6 3.8 4.9 NA NA NA Douketis et al. [21] 0.6 0.5 0.5 4.6 3.8 5.1 NA NA NA Zhu et al. [22] incidence of each event in the specified study sample, percentage event rate was calculated or adopted from the results. Mean event rate was calculated latter to ease the comparison between warfarin and dabigatran.
Three out of 17 studies were excluded from the data interpretation due to the absence of data on dabigatran 110 mg (Ezekowitz et al., Lip et al.) and event rate (Eikelboom et al.) .
RESULTS

Search results
The stepwise literature search process was illustrated in Figure 1 . Initially, 298 entries were generated of which the title and abstract were screened as per the inclusion and exclusion criteria. From these, 235 were excluded because their content was out of the scope of the review. Full-text or abstract of the remaining 63 studies was further analyzed. Seventeen studies met the inclusion or exclusion criteria (15 full-text articles, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] 23] one conference abstracts, [24] and one letter to the editors). [22] Table 2 summarizes the relevant information retrieved from the selected trials.
Efficacy and safety of dabigatran versus warfarin
The primary efficacy outcome was stroke [ Table 3 ] while the primary safety outcome was major bleeding [ Table 4 ]. Likewise, net clinical benefit which was the composite of non-CNS systemic embolism, pulmonary embolism, hemorrhagic stroke, subdural bleeding, major extracranial bleeding, myocardial infarction, and death [12] was also compared in five studies [ Table 5 ]. Data interpretation of endpoints and net clinical benefit of dabigatran and warfarin were shown in Table 1 .
Stroke
Mean incidence rate for stroke was calculated from 13 studies. [9] [10] [11] [12] [13] [14] [15] [16] 18, 19, 21, 22, 24] Warfarin had the highest mean event rate (0.6) followed by dabigatran 110 mg (0.5) and 150 mg (0.4).
Major Bleeding
Among 14 studies, [9-19,21,22,24,] warfarin caused the highest bleeding rate (mean event rate: 1.2) followed by dabigatran 150 mg (mean event rate: 1.1) and dabigatran 110 mg (mean event rate: 0.9).
Net clinical benefit
Among four studies, [11, 17, 21, 24] warfarin had the highest mean event rate (0.7) followed by dabigatran 110 mg (0.6). Dabigatran 150 mg had the least net clinical benefit (0.5).
DISCUSSION
Based on the mean event rate calculated in the result, warfarin had the highest risk of stroke occurrence compared to dabigatran 110 mg and 150 mg. . On one hand, comparison between both doses of dabigatran revealed the fact that lower dose has higher safety profile than higher dose based on the observation of less hemorrhage events (Yang et al., Hart et al.) . Apart from the efficacy and safety parameters, data analysis in terms of net clinical benefit, which is a combination of non-CNS systemic embolism, pulmonary embolism, hemorrhagic stroke, subdural bleeding, major extracranial bleeding, myocardial infarction, and death, also proposed that warfarin has less favorable clinical outcome with high-risk benefit ratio (Eikelboom et al.) . In general, the incidence of major bleeding was higher than thromboembolic events in all treatment groups, suggesting the high inherent adverse effect of both warfarin and dabigatran despite attaining therapeutic efficacy. However, we were unable to determine the significance of the result generated because we did not perform statistical analysis on the significance of each mean event rate. To summarize, warfarin is less beneficial than dabigatran based on our findings. Further exhaustive statistical interpretation is required to confirm on the significance of the findings.
Warfarin has been established as the primary antithrombotic agent in relation to the treatment protocol of AF in patient with pronounced risk of stroke or TE. [3] For instance, ACTIVE-W trial provided evidence that antiplatelet agent was inferior to warfarin, suggesting the potential benefit to give warfarin in patients with coagulation disorder. [25] In spite of excellent anticoagulation effect, warfarin was known to be leading into serious hemorrhage complications. To illustrate, there was significantly higher incidence of intracranial bleeding with warfarin (0.74%) compared with dabigatran (110 mg: 0.23%, 150 mg: 0.30%) in the RE-LY trial. This could be attributed to the different mechanism of action of both antithrombotic agents. Tissue factor (TF) is a transmembrane receptor for factor VIIa which has substantial concentration in the brain for additional hemostatic protection. [26, 27] The formation of TF-VIIa complexes as a result of interaction between activated coagulation factor VII and TF is the key initiator for cellular coagulation. Warfarin broadly inhibits carboxylation of coagulation factors II, VII, IX, and X, resulting in diminished production of factor VIIa and the subsequent suppression of TF VIIa-mediated thrombosis. [14] By comparison, dabigatran may preserve the hemostatic mechanisms in the brain by selectively inhibiting thrombin. [14] This leads to less risk of intracranial bleeding observed in the RE-LY trial. However, TF is also found in reasonably high concentration at the site of atherosclerotic plaque. [26, 27] This explains why warfarin appears to be more beneficial than dabigatran in reducing risk of myocardial infarction in the RE-LY trial.
However, warfarin is recognized to have a narrow therapeutic index with highly variable inter-and intra-individual anticoagulant response; therefore, it is necessary to regularly monitor INR and adjust the doses accordingly. [28] Certain factors such as potential drug-drug and drug-food interaction and genetic deficiency of certain enzymes involved in the metabolism of warfarin may lead to slow onset and offset of action. These further complicate the dosing regimen and limit the use of warfarin in clinical setting. [28] Therefore, a new oral anticoagulant with predictable pharmacokinetic and pharmacodynamics profile signifies huge improvement to the current anticoagulation therapy. Dabigatran, a potent direct thrombin inhibitor, is given as an orally available prodrug (dabigatran etexilate). Peak plasma concentration follows 0.5-2 h after administration, leading to rapid onset of action observed. This feature coupled with the simple twice daily dosing offers an ideal alternative for prevention of stroke. In the RE-LY trial, about one-third less risk of intracranial hemorrhage without change in efficacy against thromboembolic occurrence was found in dabigatran compared with warfarin. Overall, it is seen that the main benefits of dabigatran are the immediate onset of action and low risk of intracranial hemorrhage which is perhaps the prime concerns while using anticoagulants among AF patients. All these may advocate the superiority of dabigatran when compared with warfarin.
The main problem associated with dabigatran is the absence of antidote to reverse its antihemostatic effect. [16] This could bring a worse prognosis than warfarin in terms of major hemorrhage. Besides, patient may not be able to tolerate gastrointestinal symptoms presented as a common adverse effect of dabigatran. In the RE-LY trial, rate of discontinuation due to dyspepsia in dabigatran (110 mg: 11.8%; 150 mg: 11.3%) was almost double than that in warfarin (5.8%). [9] In addition, the incidence of gastrointestinal bleeding increased with the higher dabigatran dose with the exception of lower rate at other sites. [9] Generally, lower pH is favorable for the absorption of dabigatran. Hence, dabigatran capsules are formulated to contain dabigatran-coated pellets with a tartaric acid core. [9] This acidity may explain the common dyspeptic symptoms and gastrointestinal hemorrhage associated with dabigatran. In contrast, unabsorbed warfarin does not have bleeding concern because warfarin needs to be metabolized by hepatic enzymes to exert an anticoagulant effect. [19] Moreover, there was an increase of about 10% in mean serum creatinine in patient taking dabigatran in the trial conducted by Lip et al. [23] The inhibition of active renal tubular creatinine secretion via human organic cation transporter 2 protein may be contributing to the increased serum creatinine observed. [23] However, this is unlikely to be a real issue given its modest magnitude. [23] In terms of cost-effectiveness, high dose dabigatran (150 mg) was shown to be inferior (≤42,386 per quantity adjusted life years gained) compared with warfarin in patients whose INR is well managed or in centers that achieve good INR control. [13] There are several strengths and limitations pertaining to this review. Strength of this review is the inclusion of RCT as the main types of study to generate the findings. Based on the topic, the effect of two interventions (exposure of warfarin and dabigatran) observed in a defined context (patients with AF) would be discussed. Therefore, RCT is preferred because it provides the strongest evidence for concluding net benefit of particular intervention. Next, large sample size of all trials in this review signifies high generalizability and reproducibility of the results. Then, consistent and similar adjudication of endpoints by medical experts was also emphasized in every trial. After that, homogeneity of data was observed in both endpoints.
Nonetheless, there are several important limitations which might compromise the quality of the review. First, most trials included were subgroup analysis of RE-LY trials. Inadequate independent trials in recent years had led to the decision to include subgroup analysis in our findings. Consequently, our analysis might be limited by the similarity in RCT data. Second, the comparison of treatment effects might be limited by the low event rates observed across the trials. This was resolved by implementation of mean event rate in the interpretation of data. Third, there was absence of complete statistical data, especially P value of the endpoints in some studies. This resulted in inadequacy of information to verify the significance of data exhibited, and subsequently, a sound conclusion on the comparison could not be drawn. Therefore, results from our review should be interpreted as hypothesis and should be confirmed with comprehensive statistical interpretation.
CONCLUSION
Dabigatran (110 mg and 150 mg) was shown to have lower rate of thromboembolic complications and major bleeding than warfarin in patient with AF, suggesting the positive benefit profile of dabigatran in clinical setting. Hence, among patients where warfarin is not appropriate as the first choice, dabigatran can be an alternative. However, clinical significance of dabigatran is doubtful among population of low socioeconomic profile.
Alternatively, rate of hemorrhagic complication in warfarin could be reduced through professional counseling on drug-drug and drug-food interactions, precaution in taking the medication, and importance of adherence. There was also recommendation to compare warfarin and dabigatran in real world setting, especially at clinic operated by pharmacist focusing on warfarin as the mainstay of prevention of TE. In short, further prospective and RCTs are still required to confirm on the significance of these findings.
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